NASDAQ:CYANCyanotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cyanotech Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.10 0.00 (0.00 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$2.03Now: $2.10▼$2.1350-Day Range$2.04MA: $2.20▼$2.3652-Week Range$1.82Now: $2.10▼$3.35Volume2,764 shsAverage Volume4,114 shsMarket Capitalization$12.45 millionP/E RatioN/ADividend YieldN/ABeta0.61 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, as well as directly to consumers; and in bulk quantities to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cyanotech. Previous Next 2.4 Community Rank Outperform VotesCyanotech has received 128 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCyanotech has received 139 “underperform” votes. (Add your “underperform” vote.)Community SentimentCyanotech has received 52.06% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cyanotech and other stocks. Vote “Outperform” if you believe CYAN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYAN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCyanotech does not currently pay a dividend.Dividend GrowthCyanotech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyanotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 27.10% of the stock of Cyanotech is held by insiders.Percentage Held by InstitutionsOnly 12.64% of the stock of Cyanotech is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyanotech is -10.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyanotech is -10.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyanotech has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYAN Previous Symbol CUSIPN/A CIK768408 Webwww.cyanotech.com Phone808-326-1353Debt Debt-to-Equity Ratio0.63 Current Ratio2.10 Quick Ratio0.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$30.20 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$2.55 per share Price / Book0.82Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,600,000.00 Net Margins-4.12% Return on Equity-7.93% Return on Assets-3.77%Miscellaneous Employees118 Outstanding Shares5,930,000Market Cap$12.45 million Next Earnings Date7/6/2020 (Estimated) OptionableNot Optionable NASDAQ:CYAN Rates by TradingView Receive CYAN News and Ratings via Email Sign-up to receive the latest news and ratings for CYAN and its competitors with MarketBeat's FREE daily newsletter. Cyanotech (NASDAQ:CYAN) Frequently Asked Questions How has Cyanotech's stock been impacted by COVID-19 (Coronavirus)? Cyanotech's stock was trading at $1.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYAN shares have increased by 5.5% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus. When is Cyanotech's next earnings date? Cyanotech is scheduled to release its next quarterly earnings announcement on Monday, July 6th 2020. View our earnings forecast for Cyanotech. How were Cyanotech's earnings last quarter? Cyanotech Corp (NASDAQ:CYAN) announced its quarterly earnings results on Tuesday, February, 11th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter. The biotechnology company earned $7.50 million during the quarter. Cyanotech had a negative net margin of 4.12% and a negative return on equity of 7.93%. View Cyanotech's earnings history. Has Cyanotech been receiving favorable news coverage? Media stories about CYAN stock have trended negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyanotech earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCyanotech. Are investors shorting Cyanotech? Cyanotech saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 8,000 shares, an increase of 233.3% from the April 30th total of 2,400 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is presently 0.6 days. Approximately 0.2% of the shares of the stock are short sold. View Cyanotech's Current Options Chain. Who are some of Cyanotech's key competitors? Some companies that are related to Cyanotech include Natural Alternatives International (NAII), Mannatech (MTEX), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ). View all competitors. What other stocks do shareholders of Cyanotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyanotech investors own include Clarivate Analytics (CCC), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Bausch Health Companies (BHC), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), NovaBay Pharmaceuticals (NBY) and NovaBay Pharmaceuticals (NBY). Who are Cyanotech's key executives? Cyanotech's management team includes the following people: Mr. Mawae R. Morton, Chief Exec. Officer (Age 52)Dr. Gerald R. Cysewski Ph.D., Co-Founder, Pres & Vice Chairman (Age 70)Mr. Brian Brett Orlopp, VP of Fin. & CFO and Sec.Mr. Glenn D. Jensen, VP of Manufacturing & Infrastructure (Age 61) What is Cyanotech's stock symbol? Cyanotech trades on the NASDAQ under the ticker symbol "CYAN." Who are Cyanotech's major shareholders? Cyanotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (0.25%). View institutional ownership trends for Cyanotech. Which institutional investors are selling Cyanotech stock? CYAN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Cyanotech. How do I buy shares of Cyanotech? Shares of CYAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cyanotech's stock price today? One share of CYAN stock can currently be purchased for approximately $2.10. How big of a company is Cyanotech? Cyanotech has a market capitalization of $12.45 million and generates $30.20 million in revenue each year. Cyanotech employs 118 workers across the globe. What is Cyanotech's official website? The official website for Cyanotech is www.cyanotech.com. How can I contact Cyanotech? Cyanotech's mailing address is 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA KONA HI, 96740. The biotechnology company can be reached via phone at 808-326-1353 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
